ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting

    Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)

    P.H.P. de Jong1, J.M.W. Hazes2, K.H. Han3, A.M. Huisman4, D. van Zeben5, P.A. van der Lubbe6, A.H. Gerards6, B. van Schaeybroeck7, P.B. de Sonnaville8, M.V. Krugten9, J.J. Luime2 and A.E.A.M. Weel3, 1Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 3Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 4Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 5Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 6Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 7Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, 8Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 9Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands

    Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…
  • Abstract Number: 1694 • 2013 ACR/ARHP Annual Meeting

    A Randomised Trial Of A Brace For Patellofemoral Osteoarthritis Targeting Knee Pain and Bone Marrow Lesions

    David T. Felson1,2, Matthew J. Parkes1, Andrew D. Gait3, Elizabeth J. Marjanovic3, Mark Lunt4, Charles E. Hutchinson5, Laura Forsythe6, Timothy F. Cootes3 and Michael Callaghan1, 1Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, 2Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 3Imaging Sciences, School of Cancer & Enabling Sciences, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 5Warwick Medical School, University of Warwick, Coventry, United Kingdom, 6Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Patellofemoral (PF) braces have been shown to increase contract area in this joint, decreasing focal stress  and may also correct patellar malalignment. Bone marrow…
  • Abstract Number: 1695 • 2013 ACR/ARHP Annual Meeting

    Ustekinumab Is Effective In Inhibiting Radiographic Progression In Patients With Active Psoriatic Arthritis:  Integrated Data Analysis Of Two Phase 3, Randomized, Placebo-Controlled Studies

    Iain B. McInnes1, Christopher T. Ritchlin2, Proton Rahman3, Lluis Puig4, Alice B. Gottlieb5, Michael Song6, Bruce Randazzo6, Shu Li6, Yuhua Wang6, Alan M. Mendelsohn7 and Arthur Kavanaugh8, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 3Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 4Universitat Autònoma de Barcelona, Barcelona, Spain, 5Tufts Medical Center, Boston, MA, 6Janssen Research & Development, LLC., Spring House, PA, 7Immunology, Janssen Research & Development, LLC., Spring House, PA, 8University of California San Diego, San Diego, CA

    Background/Purpose: We describe the effect of ustekinumab (UST), an IL-12/23 p40 inhibitor, on inhibition of progression of structural damage in patients with active psoriatic arthritis…
  • Abstract Number: 1696 • 2013 ACR/ARHP Annual Meeting

    Prevalence and Incidence of Systemic Lupus Erythematosus in a Population-Based Registry of American Indian and Alaska Native People in the United States, 2007-2009

    Elizabeth D. Ferucci1, Janet Johnston2, Jasmine Gaddy3, Lisa Sumner4, James Posever4, Tammy L. Choromanski1, Caroline Gordon5, S. Sam Lim6 and Charles G. Helmick7, 1Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, 2Institute for Circumpolar Health Studies, Univeristy of Alaska Anchorage, Anchorage, AK, 3Medicine/Rheumatology, Oklahoma City Area Indian Health Service, Oklahoma City, OK, 4Medicine/Rheumatology, Phoenix Indian Medical Center, Phoenix, AZ, 5Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, 6Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, 7National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA

    Background/Purpose:   Estimates of the prevalence and incidence of systemic lupus erythematosus (SLE) have varied widely but have consistently been high in women and minority…
  • Abstract Number: 1697 • 2013 ACR/ARHP Annual Meeting

    Are Patients With Rheumatoid Arthritis Still At An Increased Risk Of Tuberculosis and What Is The Role Of Biological Treatment?

    Elizabeth V. Arkema1, Jerker Jonsson2, Eva Baecklund3, Maud Rutting4, Judith Bruchfeld5, Nils Feltelius4 and Johan Askling1,6, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Swedish Institute for Communicable Disease Control, Solna, Sweden, 3Department of Medical Sciences, Rheumatology, Uppsala University Hospital, Uppsala, Sweden, 4Swedish Medical Products Agency, Uppsala, Sweden, 5Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, 6Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose:   Anti-TNF therapy is a risk factor for clinical tuberculosis (TB), which has led to pre-treatment screening and increased vigilance. The extent to which…
  • Abstract Number: 1698 • 2013 ACR/ARHP Annual Meeting

    Sex-Related Differences and Trends In Mortality Of Juvenile-Onset Systemic Lupus Erythematosus (SLE) In The United States Over The Last Forty Years, 1971-2010

    Eric Y. Yen1, Jennifer M.P. Woo2 and Deborah K. McCurdy3, 1Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, 2Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, 3Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA

    Background/Purpose:  To date, SLE-specific mortality studies in children and adolescents are few.  Estimations of mortality in adult cohorts of SLE patients have shown that male…
  • Abstract Number: 1699 • 2013 ACR/ARHP Annual Meeting

    Development Of Systemic Lupus Erythamatosus Among “Possible Systemic Lupus Erythamatosus ” Patients Seen In Consultation: Long-Term Follow-Up

    May Al Daabil1, Bonnie L. Bermas1, Tabatha Norton1, Hsun Tsao1, Patricia Ho1, Joseph F. Merola1, Peter H. Schur1, Elena M. Massarotti1 and Karen H. Costenbader2, 1Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatology consultation to rule out SLE is common. However, in a substantial proportion of patients, SLE can be neither confirmed nor ruled out at…
  • Abstract Number: 1700 • 2013 ACR/ARHP Annual Meeting

    Which Are The Most Common Disease Modifying Antirheumatic and Biologic Treatment Pathways For Rheumatoid Arthritis Patients?

    Sofia Pedro1, Frederick Wolfe1, James O' Dell2 and Kaleb Michaud3, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: While guidelines and cost effectiveness analyses assume limited pathways for RA treatment, there is little known about what occurs in clinical practice. We sought…
  • Abstract Number: 1702 • 2013 ACR/ARHP Annual Meeting

    Identification of Multiple Genetic Susceptibility Loci in Takayasu’s Arteritis

    Guher Saruhan-Direskeneli1, Travis Hughes2, Patrick S. Coit2, Joel M. Guthridge3, Judith A. James4, Peter A. Merkel of behalf of the Vasculitis Clinical Research Consortium5, Haner Direskeneli on behalf of the Turkish Takayasu Study Group6 and Amr H. Sawalha2, 1Department of Physiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 6Department of Rheumatology, Marmara University, Faculty of Medicine, Istanbul, Turkey

    Background/Purpose: Takayasu’s arteritis is a rare inflammatory disease of large arteries. The etiology of Takayasu’s arteritis remains poorly understood, but genetic contribution to the disease…
  • Abstract Number: 1703 • 2013 ACR/ARHP Annual Meeting

    High Density Genotyping Of Immune-Related Disease Genes Identifies 7 New Susceptibility Loci For Behçet’s Disease

    Masaki Takeuchi1,2, Nobuhisa Mizuki2, Akira Meguro2, Michael J. Ombrello3, Colleen Satorius4, Yohei Kirino2, Tatsukata Kawagoe2, Duran Ustek5, Ilknur Tugal-tutkun6, Emire Seyahi7, Yilmaz Ozyazgan7, Shigeaki Ohno8, Atsuhisa Ueda2, Yoshiaki Ishigatsubo2, Ahmet Gül6,9, Daniel L. Kastner4 and Elaine Remmers4, 1Medical Genetics Branch, Inflammation Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 2Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Translational Genetics and Genomics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 5Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, 6Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 7Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, 8Hokkaido University Graduate School of Medicine, Hokkaido, Japan, 9Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

    Background/Purpose: Genome-wide association studies have revealed susceptibility genes for many genetically complex diseases. The Immunochip is a custom array with 196,524 markers in 186 loci…
  • Abstract Number: 1704 • 2013 ACR/ARHP Annual Meeting

    Mapping The Shared and Distinct HLA Alleles For Seropositive and Seronegative Rheumatoid Arthritis

    Buhm Han1, Stephen Eyre2, Dorothee Diogo1, John Bowes3, Yukinori Okada1, Leonid Padyukov4, Robert M. Plenge5, Lars Klareskog6, Jane Worthington7, Peter K. Gregersen8, Paul de Bakker9 and Soumya Raychaudhuri1, 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 4Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 5Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 6Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 7Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 8Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 9Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Investigators have long speculated that the two subtypes of rheumatoid arthritis (RA), anti-citrullinated protein autoantibody positive (ACPA+) and negative (ACPA-), have distinct underlying genetic…
  • Abstract Number: 1705 • 2013 ACR/ARHP Annual Meeting

    Genetic Associations In Anterior Uveitis Implicate T-Cell Co-Stimulation and Other Immune Pathways

    Philip Robinson1, Dorith Claushuis2, Paul Leo1, Pamela Mukhopadhyay3, P. Wordsworth4,5, Michael H. Weisman6, Walter P. Maksymowych7, Proton Rahman8, Robert Inman9, Alex Hewitt10, Tammy M. Martin11, James T. Rosenbaum12, Dennis Wakefield13, John D. Reveille14 and Matthew A. Brown15, 1Human Genetics Group, University of Queensland Diamantina Insititute, Brisbane, Australia, 2Human Genetics Group, The University of Queensland Diamantina Institute, Brisbane, Australia, 3Human Genetics Group, The University of Queensland Diamantina Insititute, Brisbane, Australia, 4Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 5Nuffield Orthopaedic Centre, Oxford, United Kingdom, 6Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 7Medicine, University of Alberta, Edmonton, AB, Canada, 8Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 9Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada, 10Lions Eye Institute, University of Western Australia, Perth, Australia, 11Ophthalmology/L467AD, Oregon Health & Science Univ, Portland, OR, 12Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, 13Faculty of Medicine, University of New South Wales, Sydney, Australia, 14Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 15University of Queensland Diamantina Institute, Brisbane, Australia

    Background/Purpose: Anterior uveitis (AU) complicates a number of autoimmune diseases including ankylosing spondylitis (AS), Behcet’s disease and sarcoidosis. It is highly heritable and HLA-B27 is…
  • Abstract Number: 1681 • 2013 ACR/ARHP Annual Meeting

    Assessment of Patients With Takayasu’s Arteritis in Routine Clinical Follow-Up With Indian Takayasu Clinical Activity Score 2010(ITAS2010)

    Fatma Alibaz-Oner and Haner Direskeneli, Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: ITAS2010 (Indian Takayasu Clinical Activity Score) is a new composite index developed to assess clinical activity in Takayasu’s arteritis (TAK), which is weighted for…
  • Abstract Number: 1665 • 2013 ACR/ARHP Annual Meeting

    B Cells Revisited In Giant Cell Arteritis

    Kornelis S.M. van der Geest1, Wayel H. Abdulahad2, Gerda Horst2, Caroline Roozendaal3, Abraham Rutgers2, Annemieke M.H. Boots2 and Elisabeth Brouwer2, 1Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 3Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) is a primary vasculitis affecting large to medium-sized arteries. Ample evidence suggests that dendritic cells, T cells and monocytes/macrophages contribute…
  • Abstract Number: 1666 • 2013 ACR/ARHP Annual Meeting

    Negative Temporal Artery Biopsies: Pathologic Findings Of Patients With Biopsy-Negative Giant Cell Arteritis Compared To Those Of Patients Without Arteritis

    Francesco Muratore1, Alberto Lo Gullo1, Alberto Cavazza2, Giuseppe Germanò1, Luigi Boiardi1 and Carlo Salvarani3, 1Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 2Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 3Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy

    Background/Purpose: Temporal artery biopsy (TAB) showing transmural inflammation is considered the gold  standard for the diagnosis of giant cell arteritis (GCA). A negative TAB does…
  • « Previous Page
  • 1
  • …
  • 2318
  • 2319
  • 2320
  • 2321
  • 2322
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology